scispace - formally typeset
Y

Yanan Zhang

Researcher at Research Triangle Park

Publications -  96
Citations -  1964

Yanan Zhang is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Agonist & Receptor. The author has an hindex of 26, co-authored 88 publications receiving 1628 citations. Previous affiliations of Yanan Zhang include RTI International & University at Buffalo.

Papers
More filters
Journal ArticleDOI

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Thuy Nguyen, +5 more
- 01 May 2017 - 
TL;DR: Given the psychoactive effects commonly associated with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands.
Journal ArticleDOI

Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats.

David A. Thorn, +7 more
- 18 Apr 2014 - 
TL;DR: The first systematic assessment of a TAAR 1 agonist on a range of behavioral effects of cocaine, showing that RO5263397 was efficacious in reducing cocaine-mediated behaviors is reported, and essential neuromodulatory roles of TAar 1 on cocaine abuse are uncovered.
Journal ArticleDOI

Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.

Yanan Zhang, +6 more
- 14 Oct 2010 - 
TL;DR: A library of bivalent ligands composed of two identical CB1 antagonist pharmacophores derived from SR141716 linked by spacers of various lengths suggest that the nature of the linker and its length are crucial factors for optimum interactions of these ligands at CB1 receptor binding sites.
Journal ArticleDOI

Imidazoline I2 receptors: target for new analgesics?

Jun-Xu Li, +1 more
- 11 May 2011 - 
TL;DR: I(2) receptor ligands can attenuate the development of tolerance to opioid analgesia and inhibit drug withdrawal or antagonist precipitation induced abstinence syndrome in animals and may be useful as a monotherapy or combined with opioids as an adjuvant for treating pain.
Journal ArticleDOI

Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.

Alan Fulp, +7 more
- 09 Mar 2012 - 
TL;DR: These efforts aimed at rationally designing peripherally restricted CB1 antagonists have resulted in compounds that have limited blood-brain barrier permeability and CNS exposure in preclinical in vitro and in vivo models.